The Colorado Consortium for Prescription Drug Abuse Prevention coordinates Colorado’s response to the misuse of medications such as opioids, stimulants, and sedatives. The Consortium’s mission is to reduce prescription drug misuse and abuse in Colorado by developing policies, programs, and partnerships with the many state agencies, organizations, and community coalitions addressing one of Colorado’s major public health crises.

The Consortium is supported by and located at the University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences at the CU Anschutz Medical Campus. Our external relations staff live and work in local communities representing four regions of the state, allowing us to best facilitate a statewide approach.

This educational program consists of self-study education modules that healthcare providers can complete at their own pace.

Colorado Consortium Contact: Jessica Eaddy [email protected]

Group visibility: 
Public - accessible to all site users

Enduring courses

Title Credit Cost Start and Expiration Dates
Anatomy of an Inpatient Addiction Consultation
    • 1.00 AMA PRA Category 1 Credit™
$0.00 04/28/2025 - 9:01am to 04/27/2028 - 11:59pm
2022 CDC Clinical Practice Guideline for Prescribing Opioids for Oral and Dental Pain
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
A Deeper Dive into the CDC Guidelines: Implementation and Practice
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
Benzodiazepine Induced Neurological Dysfunction (BIND)
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
Higher Dose Buprenorphine
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
Introduction to Substance Use Disorders & Medication-Assisted Treatment
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
Psychological Factors Influencing the Transition from Acute to Chronic Pain
    • 1.00 AMA PRA Category 1 Credit™
$0.00 03/19/2025 - 12:01am to 03/18/2028 - 11:59pm
Benzodiazepines: Appropriate Prescribing & Alternative Treatments
    • 0.50 AMA PRA Category 1 Credit™
$0.00 01/01/2025 - 12:01am to 12/31/2027 - 11:59pm
Deprescribing/Tapering of Prescription Benzodiazepines
    • 1.00 AMA PRA Category 1 Credit™
$0.00 01/01/2025 - 12:01am to 12/31/2027 - 11:59pm
Non-Opioid Pain Management
    • 0.50 AMA PRA Category 1 Credit™
$0.00 01/01/2025 - 12:01am to 12/31/2027 - 11:59pm
Physical Therapy for Pain Management
    • 0.50 AMA PRA Category 1 Credit™
$0.00 01/01/2025 - 12:01am to 12/31/2027 - 11:59pm
Clinical Pearls of Opioid Prescribing
    • 1.00 AMA PRA Category 1 Credit™
$0.00 12/31/2024 - 11:01pm to 12/31/2027 - 10:59pm

Continuing Medical Education (CME)

Accreditation: This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Iowa Medical Society (IMS) through the joint providership of Compass Healthcare Collaborative (Compass) and The University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences - Colorado Consortium for Prescription Drug Abuse Prevention. The Compass Healthcare Collaborative (Compass) is accredited by the IMS to provide continuing medical education for physicians.

Commercial Support: This activity was developed without support from any ineligible company. *The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Note: The ACCME does not consider providers of clinical service directly to patients to be commercial interests unless the provider of clinical services is owned, or controlled by, and ACCME defined ineligible company.

Disclosure: Compass adheres to the Standards for Integrity and Independence in Accredited Continuing Education. The content of this activity is not related to products or the business lines of an ACCME-defined ineligible company. None of the planners or moderators for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing products used by or on patients.

Recent News

There is currently no content to view in this section.